Liability in prescribing choice: The example of the antidepressants

References

• Nisselle P. Is there a medical litigation crisis?. Medical Journal of Australia 1996; 164: 178–182
   Google Scholar
• Rogers v Whitaker. 1992, 175 CLR 479
   Google Scholar
• Hrihar v Wells. 1995, 64 SASR 129
   Google Scholar
• Howarth & Adey. 1996, 2 VR 535
   Google Scholar
• O 'Shea v Sullivan. 1994, Aust Torts Reports 81–273
   Google Scholar
• Stair and v Baker, (CA (NSW). February, 7, 1992, Priestley, Clarke and Handley J JA, No. 40778/191 unreported
   Google Scholar
• Studdert J. February 18, 1991, Putnam v Huber (SC (NSW) No. 12691/90, unreported
   Google Scholar
• Giles J. November 7, 1994, McDonell v Reed (SC (NSW)No. 0470/94. unreported
   Google Scholar
• Thomas J. 13 April, 1995, Sturch v Willmott (SC (Qld) No. 1302/94 unreported
   Google Scholar
• Lowns V Woods. 1996; 81–376, Aust Torts Reports
   Google Scholar
• Albrighton v Royal. Prince Alfred Hospital. 1980; 542, 2 NSWLR
   Google Scholar
• Frost v Board of Management of Royal Perth Hospital. C J Malcolm, J J Rowland, Wallwork, 13 June, 1996, 1995, 14 SR (NSW) 141; see also Board of Management of Royal Perth Hospital v Frost (SC(WA) and 26 February 1997, unreported No. 130/95
   Google Scholar
• Simpson J. November 25, 1994, Geissman v O'Keefe(SC (NSW) No. 15758/91, unreported)
   Google Scholar
• King C J, White J, Bollen J. January 17, 1992, Jackson v Vercoe (SC (SA), no. 2081/86. unreported
   Google Scholar
• Woods v Lowns (1995) 36 NSWLR 344
   Google Scholar
• Lipovac v Hamilton Holdings Pry Limited (SC (ACT), Higgins J, No. SC 501/93. 13 September 1996 and 17 January 1997, unreported).
   Google Scholar
• A Policy on the quality use of medicines. Pharmaceutical Health and the Rational Use of Medicines (PHARM) Committee, Commonwealth Department of Health. Housing and Community Services, Canberra 1992
   Google Scholar
• World Health Organization. Guide to good prescribing. World Health Organization, WHO Action Programme on Essential Drugs, Geneva 1995
   Google Scholar
• Davies B., Burrows G, Dumovic P. Effects on the heart of different tricyclic antidepressants. Sideburn (doxepin HCL): a monograph of recent clinical studies, J Mends. Excerpta Medica, Amsterdam 1975; 54–58
   Google Scholar
• Tobis J M, Aronow W S. Cardiotoxicity of amitriptyline and doxepin. Clinical Pharmacology and Therapeutics 1981; 29: 359–364
   PubMed Web of Science ®Google Scholar
• Vohra J, Burrows G, Hunt D, Sloman G. The effect of toxic and therapeutic doses of tricyclic antidepressant drugs on intracardiac conduction. EuropeaN Journal of Cardiology 1975; 3: 219–227
   PubMedGoogle Scholar
• Kristiansen E S. Cardiac complications during treatment with imipramine (Tofranil). Acta Psychiatrica Scandinavica 1961; 36: 427–442
   PubMedGoogle Scholar
• Moir D, Crooks C., Cornwell J. WB. Cardiotoxicity of amitriptyline. Lancet 1972; 2: 561–564
   PubMed Web of Science ®Google Scholar
• Cassidy Henry S., Fatal J. toxicity of antidepressant drugs in overdose. British Medical Journal 1987; 295: 1021–1024
   PubMed Web of Science ®Google Scholar
• Rasmussen E B, Kristjansen P. ECG changes during amitriptyline treatment. American Journal of Psychiatry 1963; 119: 781–782
   PubMed Web of Science ®Google Scholar
• Barnes R J, Kong S M, Wu R WY. Electrocardiographic changes in amitriptyline poisoning. British Medical Journal 1968; 3: 222
   PubMed Web of Science ®Google Scholar
• Freeman J W, Mundy G R, Beattie R R, Ryan C. Cardiac abnormalities in poisoning with tricyclic antidepressants. British Medical Journal 1969; 2: 610
   PubMed Web of Science ®Google Scholar
• Veith R C, Raskind M A, Caldwell J H, Barnes R F, Gumbrecht G, Ritchie J L. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. New England Journal of Medicine 1982; 306: 954–959
   PubMed Web of Science ®Google Scholar
• Glassman A H, Bigger J T. Cardiovascular effects of therapeutic doses of the tricyclic antidepressants: a review. Archives of General Psychiatry 1981; 38: 815–820
   PubMed Web of Science ®Google Scholar
• Bigger J T, Giardina E GV, Perel J M, Kantor S J, Glassman A H. Cardiac antiarrhythmic effect of imipramine hydrochlo-ride. New England Journal of Medicine 1977; 296: 206–208
   PubMed Web of Science ®Google Scholar
• Burrows G D, Norman T R. Who bears the costs of antidepressants in Australia? [letter]. Medical Journal of Australia 1995; 162: 162
   Google Scholar
• Tiller J WG. Who bears the costs of antidepressants in Australia? [letter]. Medical Journal of Australia 1995; 162: 163
   Google Scholar
• Haski R R, Grainger D. Who bears the costs of antidepressants in Australia? [letter]. Medical Journal of Australia 1995; 162: 164
   Google Scholar
• Montgomery S, Kasper A. S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. International Clinical Psychopharmacology 1995; 9(Suppl. 4)33–40
   PubMed Web of Science ®Google Scholar
• Angst J, Stabl M. Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 1992; 106: S109–S113
   Web of Science ®Google Scholar
• Delini-Stula A, Mikkelsen Angst H.J. Therapeutic efficacy of antidepressants in agitated anxious depression—a meta-analysis of moclobcmide studies. Journal of Affective Disorders 1995; 35: 21–30
   Google Scholar
• Leonard B E. Pharmacological differences of serotonin reup take inhibitors and possible clinical relevancc. Drugs 1992; 43: 3–10
   PubMedGoogle Scholar
• Auster R. Sertraline a new antidepressant. American Family Physician 1993; 48: 311–314
   Google Scholar
• Buckley N A, Shyte I M, Dawson A H, McManus P R, Ferguson N W. Self-poisoning in Newcastle, 1987–1992. Medical Journal of Australia 1995; 162: 194–196
   PubMed Web of Science ®Google Scholar
• Myers L B, Dean B S, Krenzelok E P. Sertraline: a pediatric overdose approach [abstract]. Veterinary and Human Toxicology 1994; 36: 361
   Google Scholar
• Spyker D A, Cantilena L R. Cardiovascular and CNS adverse events for Antidepressants Reported to the FDA [abstract]. Clinical Pharmacology and Therapeutics 1995; 57: 190
   Google Scholar
• Doogan D P. Toleration and safety of sertraline: experience worldwide. International Clinical Pharmacology 1991; 6(SUPP 2)47–56
   Google Scholar
• Brown D F, Kerr H D. Sertraline overdose [case report]. Annals of Pharmacotherapy 1994; 28: 1307
   PubMed Web of Science ®Google Scholar
• Caracci G. Unsuccessful suicide attempt by sertraline over dose (letter]. American Journal of Psychiatry 1994; 151: 1
   Google Scholar
• Henry J A, Alexander C A, Sener E K. Relative mortality from overdose of antidepressants. British Medical Journal 1995; 310: 221–224
   PubMed Web of Science ®Google Scholar
• Klein-Schwartz W, Anderson B. Analysis of sertraline only overdoses [abstract]. Veterinary and Human Toxicology 1984; 36: 378
   Google Scholar
• Berti C, Ward R A, Byfield R, Henry J A. Evaluation of ser traline overdoses reported in the United Kingdom. Presented at the European Medical Research Group Meeting (part of the European Association of Internal Medicine), London, July, 111994
   Google Scholar
• Goldney R D, Trowse M M, Chia M M. Saving of SSRI over dose [letter]. Medical Journal of Australia 1995; 162: 668–669
   Google Scholar
• Mitchell P B. The new antidepressants: a guide for GPs. Modern Medicine (Australia) Dec, 1994; 16–20
   Google Scholar
• Mitchell P B. Selective serotonin reuptake inhibitors. Fantasies and controversies. Current Therapeutics April, 1995; 9–13
   Google Scholar
• Mitchell P B. The new antidepressants—are they worth the cost?. Australian Prescriber 1995; 18: 82–84
   Google Scholar
• Goldney R D. Who hears the costs of antidepressants in Australia? [letter]. Medical Journal of Australia 1995; 162: 162
   Google Scholar
• White B. Who hears the costs of antidepressants in Australia? [letter]. Medical Journal of Australia 1995; 162: 163
   Google Scholar
• Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. British Journal of Psychiatry 1967; 113: 349–365
   PubMed Web of Science ®Google Scholar
• Tiller J WG. The new antidepressants. Australian Prescriber 1995; 18: 92–96
   Google Scholar
• Stokes P E. Fluoxetine: a five year review. Clinical Therapeutics 1993; 15: 216–243
   Google Scholar
• Johnson D AW. Depression: treatment compliance in general practice. Acta Psychiatrica Scandinavica 1981; 63: 447–453
   Google Scholar
• Kerr J S, Fairweather D B, Hindmarch I. Medicines and accidents. The Safety and Health Practitioner 1992; 10: 17–18
   Google Scholar
• Hindmarch I, Subhan Z, Stoker M J. Effects of zimeldine and amitriptyline on car driving and psychomotor performance. Acta Psychiatrica Scandinavica 1983; 308: 141–146
   Google Scholar
• Ashford J J. Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as ‘new’ drugs with established fluvoxamine?. International Clinical Psychopharmacology 1995; 9(Suppl. 4)27–31
   Google Scholar
• Bolam V Friem Hospital Management Committee1957. Sidaway v Governors of Bethlem Royal Hospital. 1985, 1 WLR 582; see also 1 AC 871, 880 per Lord Scarman
   Google Scholar
• Mitchell P B, Mitchell M S. The management of depression. Part 2. The place of the new antidepressants. Australian Family Physician 1994; 23: 1771–1781
   Google Scholar
• F v R (1983) 33 SASR 189, 196 per King CJ; 207 per Bollen J.
   Google Scholar
• Alchin T M, Tranby H W. Who bears the cost of antidepres sants in Australia?. Medical Journal of Australia 1994; 161: 547–549
   PubMed Web of Science ®Google Scholar
• Jonsson B, Bobbington P E. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. British Journal of Psychiatry 1994; 164: 665–673
   PubMed Web of Science ®Google Scholar
• Wong Shire Council v Shirt (1980) 146 CLR 40,4748 per Mason J .
   Google Scholar